Transcriptomic Heterogeneity of Gleason Grade Group 5 Prostate Cancer[Formula presented]

Amar U. Kishan*, Tahmineh Romero, Mohammed Alshalalfa, Yang Liu, Phuoc T. Tran, Nicholas G. Nickols, Huihui Ye, Dipti Sajed, Matthew B. Rettig, Robert E. Reiter, Isla P. Garraway, Daniel E. Spratt, Steven J. Freedland, Xin Zhao, Ziwen Li, Matthew Deek, Julie Livingstone, Brandon A. Mahal, Paul L. Nguyen, Felix Y. FengRobert B. Den, Edward M. Schaeffer, Tamara L. Lotan, R. Jeffrey Karnes, Eric A. Klein, Ashley E. Ross, Tristan Grogan, Elai Davicioni, David Elashoff, Paul C. Boutros, Joanne B. Weidhaas

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Abstract

Gleason grade group (GG) 5 prostate cancer has been associated with an aggressive natural history, and retrospective data support a role for treatment intensification. However, clinical outcomes remain heterogeneous in this cohort, and intensified treatments carry an increased risk of adverse events. We sought to explore the transcriptomic heterogeneity of GG 5 tumors by querying transcriptomic data from the tumors of 2138 patients with GG 5 disease who underwent prostatectomy. Four distinct consensus clusters were identified with respect to differential transcriptional activation of hallmark pathways, with distinct molecular subtyping profiles and different average genomic risks (AGRs). One cluster, accounting for 325 tumors (15.2% of the population), was enriched for genes related to the cell cycle/proliferation, metabolic pathways, androgen response pathways, and DNA repair, and had a higher AGR than the other clusters (p < 0.001). This clustering, with an identification of a high genomic risk cluster, was subsequently validated in a separate cohort of 1921 patients as well as a third cohort of 201 patients. The latter cohort had outcomes available, and it was found that patients in the high genomic risk cluster had significantly worse distant metastasis-free survival than the other clusters. Tumors in this high genomic risk cluster of GG 5 disease may be particularly likely to benefit from treatment intensification. Patient summary: In this report, we examined differences in gene expression in tumors from men with Gleason grade group 5 prostate cancer. We identified significant diversity, with one specific subgroup of tumors associated with expression profiles that suggest a worse prognosis.

Original languageEnglish (US)
Pages (from-to)327-332
Number of pages6
JournalEuropean urology
Volume78
Issue number3
DOIs
StatePublished - Sep 2020

Keywords

  • Biomarkers
  • Gleason grade group 5
  • Gleason score 10
  • Gleason score 9
  • Transcriptomics

ASJC Scopus subject areas

  • Urology

Fingerprint

Dive into the research topics of 'Transcriptomic Heterogeneity of Gleason Grade Group 5 Prostate Cancer[Formula presented]'. Together they form a unique fingerprint.

Cite this